Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 23398373)

1.

Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases.

Jimenez JM, Boyall D, Brenchley G, Collier PN, Davis CJ, Fraysse D, Keily SB, Henderson J, Miller A, Pierard F, Settimo L, Twin HC, Bolton CM, Curnock AP, Chiu P, Tanner AJ, Young S.

J Med Chem. 2013 Mar 14;56(5):1799-810. doi: 10.1021/jm301465a. Epub 2013 Feb 11.

PMID:
23398373
2.

Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.

Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, Greco R, Huang X, Joseph-McCarthy D, Kelly MF, Kirisits M, Lee J, Li Y, Morgan P, Stock JR, Tsao DH, Wissner A, Yang X, Chaudhary D.

J Med Chem. 2008 Oct 9;51(19):5958-63. doi: 10.1021/jm800214a. Epub 2008 Sep 11.

PMID:
18783200
3.

Through the looking glass: adventures in kinase inhibitor design and optimization.

Clark RD.

J Med Chem. 2013 Mar 14;56(5):1796-8. doi: 10.1021/jm400243u. Epub 2013 Feb 26.

PMID:
23442161
4.

PKCtheta: A potential therapeutic target for T-cell-mediated diseases.

Chaudhary D, Kasaian M.

Curr Opin Investig Drugs. 2006 May;7(5):432-7. Review.

PMID:
16729719
5.

The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression.

Zhang EY, Kong KF, Altman A.

Adv Pharmacol. 2013;66:267-312. doi: 10.1016/B978-0-12-404717-4.00006-8. Review.

6.

Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.

Shim J, Eid C, Lee J, Liu E, Chaudhary D, Boschelli DH.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6575-7. doi: 10.1016/j.bmcl.2009.10.031. Epub 2009 Oct 13.

PMID:
19854645
7.

Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.

Dushin RG, Nittoli T, Ingalls C, Boschelli DH, Cole DC, Wissner A, Lee J, Yang X, Morgan P, Brennan A, Chaudhary D.

Bioorg Med Chem Lett. 2009 May 1;19(9):2461-3. doi: 10.1016/j.bmcl.2009.03.053. Epub 2009 Mar 18.

PMID:
19345579
8.

C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II.

Prashad AS, Wang D, Subrath J, Wu B, Lin M, Zhang MY, Kagan N, Lee J, Yang X, Brennan A, Chaudhary D, Xu X, Leung L, Wang J, Boschelli DH.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5799-802. doi: 10.1016/j.bmcl.2009.07.113. Epub 2009 Jul 28.

PMID:
19703774
9.

Selective protein kinase Cθ (PKCθ) inhibitors for the treatment of autoimmune diseases.

Curnock A, Bolton C, Chiu P, Doyle E, Fraysse D, Hesse M, Jones J, Weber P, Jimenez JM.

Biochem Soc Trans. 2014 Dec;42(6):1524-8. doi: 10.1042/BST20140167.

PMID:
25399564
10.

5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity.

Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.

Bioorg Med Chem. 2009 Dec 1;17(23):7933-48. doi: 10.1016/j.bmc.2009.10.020. Epub 2009 Oct 31.

PMID:
19884013
11.

First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors.

Niu C, Boschelli DH, Tumey LN, Bhagirath N, Subrath J, Shim J, Wang Y, Wu B, Eid C, Lee J, Yang X, Brennan A, Chaudhary D.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32. doi: 10.1016/j.bmcl.2009.08.086. Epub 2009 Aug 29.

PMID:
19762237
12.

2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.

van Eis MJ, Evenou JP, Floersheim P, Gaul C, Cowan-Jacob SW, Monovich L, Rummel G, Schuler W, Stark W, Strauss A, von Matt A, Vangrevelinghe E, Wagner J, Soldermann N.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7367-72. doi: 10.1016/j.bmcl.2011.10.025. Epub 2011 Oct 21.

PMID:
22078216
13.

2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.

Nathan Tumey L, Boschelli DH, Lee J, Chaudhary D.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4420-3. doi: 10.1016/j.bmcl.2008.06.040. Epub 2008 Jun 18.

PMID:
18606543
14.

Synthesis and PKCtheta inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles.

Boschelli DH, Wu B, Barrios Sosa AC, Chen J, Asselin M, Cole DC, Lee J, Yang X, Chaudhary D.

Bioorg Med Chem Lett. 2008 May 1;18(9):2850-3. doi: 10.1016/j.bmcl.2008.03.077. Epub 2008 Apr 8.

PMID:
18434148
15.

Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCtheta inhibitors.

Boschelli DH, Wang D, Prashad AS, Subrath J, Wu B, Niu C, Lee J, Yang X, Brennan A, Chaudhary D.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3623-6. doi: 10.1016/j.bmcl.2009.04.126. Epub 2009 May 3.

PMID:
19447612
16.

PKCtheta and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes.

Hermann-Kleiter N, Thuille N, Pfeifhofer C, Gruber T, Schäfer M, Zitt C, Hatzelmann A, Schudt C, Leitges M, Baier G.

Blood. 2006 Jun 15;107(12):4841-8. Epub 2006 Mar 2.

17.

Protein kinase C-theta (PKCtheta), a potential drug target for therapeutic intervention with human T cell leukemias.

Villalba M, Altman A.

Curr Cancer Drug Targets. 2002 Jun;2(2):125-37. Review.

PMID:
12188914
18.

Small molecule inhibitors of PKCTheta as potential antiinflammatory therapeutics.

Boschelli DH.

Curr Top Med Chem. 2009;9(7):640-54. Review.

PMID:
19689371
19.

Protein kinase C-theta (PKCtheta): it's all about location, location, location.

Altman A, Villalba M.

Immunol Rev. 2003 Apr;192:53-63. Review.

PMID:
12670395
20.

Protein kinase Ctheta, a selective upstream regulator of JNK/SAPK and IL-2 promoter activation in Jurkat T cells.

Ghaffari-Tabrizi N, Bauer B, Villunger A, Baier-Bitterlich G, Altman A, Utermann G, Uberall F, Baier G.

Eur J Immunol. 1999 Jan;29(1):132-42.

PMID:
9933094
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk